Filing summary
Company identity: The supplied filing is Tivic Health Systems, Inc.’s Form 10-Q, not a filing identified as Valion Bio, Inc. Investors should verify the issuer and ticker (TIVC) before relying on this summary.
Business context and reporting period
The unaudited report covers the quarter ended March 31, 2022, with comparable results for the three months ended March 31, 2021. Tivic develops and commercializes non-invasive bioelectronic treatments. Its commercial product is ClearUP, an FDA-approved device for sinus inflammation and congestion, sold through direct-to-consumer and retail channels. The company reports U.S. GAAP interim financial statements; it cautions that quarterly results are not necessarily indicative of full-year results.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $428,000 | $323,000; up 33% |
| Gross profit / gross margin | $70,000 / 16.4% | $22,000 / 6.8% |
| Operating expenses | $2.311 million | $1.079 million |
| Operating loss | $2.241 million | $1.057 million |
| Net loss | $2.240 million | $1.356 million |
| Net loss per share | $0.23 | $0.58 |
| Cash used in operating activities | $2.168 million | $665,000 |
| Cash and cash equivalents at period end | $10.801 million | $12.975 million at Dec. 31, 2021 |
At March 31, 2022, current assets were $11.998 million and current liabilities were $1.097 million, yielding working capital of about $10.9 million. Total liabilities were $1.601 million, including $672,000 of operating lease liabilities; the filing reports no drawn debt at quarter-end. A $250,000 revolving credit line was available but undrawn. Accumulated deficit was $21.8 million.
Material changes and management commentary
- Revenue rose primarily due to a 28% increase in unit sales and changes to sales channels. Direct-to-consumer unit sales increased 77%; retail unit sales fell 26% after the company ended less profitable arrangements.
- Cost of sales increased 19%, slower than revenue growth. Management cited higher volume and lower fixed cost per unit, partly offset by higher variable cost per unit from product mix and ongoing supply-chain constraints.
- Operating expenses more than doubled: R&D increased to $401,000, sales and marketing to $684,000, and general and administrative to $1.226 million. The company attributed increases to product development and clinical work, expanded marketing, and public-company insurance and professional costs.
- The company reported 12 patients enrolled in a 60-person sham-controlled clinical trial of a treatment for postoperative pain following sinus surgery and expected to complete the study in Q4 2022. It also cited product research and design in migraine treatment.
Outlook, risks, and unusual items
- Management expects substantial additional operating losses for at least the next two years, but believes available cash and resources are sufficient for at least 12 months from issuance of the financial statements. The company says this assessment depends on assumptions that may prove incorrect and that additional financing may be needed.
- Management cannot reliably estimate timelines or costs to develop, obtain regulatory approval for, and commercialize future products, or predict when profitability may be achieved. Additional equity financing could dilute shareholders; debt could add repayment obligations and covenants.
- Supply constraints, particularly for electronic components, inflation, transportation and component-cost increases, and COVID-19-related disruptions could impair production, raise costs, or reduce margins. The filing also discusses possible broader market and supply-chain impacts from the Russia-Ukraine conflict; no material company impact was reported to date.
- The company disclosed a previously identified material weakness in internal financial controls related to limited accounting personnel, segregation of duties, and inventory cost accounting. It described remediation steps, but had not completed its full internal-control assessment.
- No material legal proceedings, contingent liabilities, or off-balance-sheet arrangements were reported. A subsequent event: on April 1, 2022, the company repurchased 93,750 unvested restricted shares from a departing employee.
Most important facts to verify
- Confirm the issuer: the filing identifies Tivic Health Systems, Inc. (Nasdaq: TIVC), despite the request naming Valion Bio, Inc.
- Assess cash runway against the reported quarterly operating cash use of $2.168 million, planned spending, and management’s 12-month liquidity assessment.
- Track revenue growth, channel mix, unit economics, gross margin, and whether supply constraints or inflation affect product availability and costs.
- Verify progress and completion of the postoperative-pain clinical trial, and the regulatory and commercial path for new product candidates.
- Review remediation of the material weakness and the reliability of inventory accounting and financial reporting controls.